Atossa Therapeutics Inc (NASDAQ: ATOS) has experienced a decline in its stock price by -2.85 compared to its previous closing price of 1.23. However, the company has seen a fall of -7.36% in its stock price over the last five trading days. globenewswire.com reported 2024-11-21 that Highlights Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds in ERα+ Breast Cancer Highlights Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds in ERα+ Breast Cancer
Is It Worth Investing in Atossa Therapeutics Inc (NASDAQ: ATOS) Right Now?
Company’s 36-month beta value is 1.21.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ATOS is 125.75M, and currently, short sellers hold a 9.90% ratio of that floaft. The average trading volume of ATOS on December 04, 2024 was 602.67K shares.
ATOS’s Market Performance
ATOS’s stock has seen a -7.36% decrease for the week, with a -15.25% drop in the past month and a -12.13% fall in the past quarter. The volatility ratio for the week is 4.40%, and the volatility levels for the past 30 days are at 6.05% for Atossa Therapeutics Inc The simple moving average for the past 20 days is -10.27% for ATOS’s stock, with a -13.93% simple moving average for the past 200 days.
Analysts’ Opinion of ATOS
Many brokerage firms have already submitted their reports for ATOS stocks, with Maxim Group repeating the rating for ATOS by listing it as a “Buy.” The predicted price for ATOS in the upcoming period, according to Maxim Group is $2 based on the research report published on January 26, 2018 of the previous year 2018.
ATOS Trading at -14.26% from the 50-Day Moving Average
After a stumble in the market that brought ATOS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -48.27% of loss for the given period.
Volatility was left at 6.05%, however, over the last 30 days, the volatility rate increased by 4.40%, as shares sank -15.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -15.36% lower at present.
During the last 5 trading sessions, ATOS fell by -8.14%, which changed the moving average for the period of 200-days by +16.18% in comparison to the 20-day moving average, which settled at $1.3312. In addition, Atossa Therapeutics Inc saw 35.80% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ATOS starting from Finn Jonathan, who purchase 25,000 shares at the price of $1.77 back on Apr 10 ’24. After this action, Finn Jonathan now owns 25,000 shares of Atossa Therapeutics Inc, valued at $44,250 using the latest closing price.
Stock Fundamentals for ATOS
Current profitability levels for the company are sitting at:
- -1638.28 for the present operating margin
- -0.28 for the gross margin
The net margin for Atossa Therapeutics Inc stands at -1495.06. The total capital return value is set at -0.4. Equity return is now at value -31.30, with -29.71 for asset returns.
Currently, EBITDA for the company is -31.35 million with net debt to EBITDA at 2.54. When we switch over and look at the enterprise to sales, we see a ratio of 4163.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.30.
Conclusion
In a nutshell, Atossa Therapeutics Inc (ATOS) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
